Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2022 16:20 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

Several anticipated catalysts in 2022 aim to advance Aileron’s vision to bring chemoprotection against multiple toxicities to all patients with p53-mutated cancer regardless of type of cancer or...
March 22, 2022 08:04 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more...
January 05, 2022 08:04 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones

Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing randomized, double-blind, placebo-controlled...
January 04, 2022 08:45 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
December 20, 2021 10:56 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

BOSTON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today issued the following statement regarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a...
November 12, 2021 07:50 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned...
October 07, 2021 09:22 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity

-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s...
September 30, 2021 16:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer...
September 16, 2021 08:15 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent

Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and...
September 10, 2021 08:30 ET | Source: Aileron Therapeutics, Inc.

Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924

Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic...